Background: The MGuard (Inspire MD, Tel Aviv, Israel ) is a bare-metal polyethylene terephthalate micronet mesh–covered stent that has been developed in order to prevent complications encountered in highly complex lesion angioplasty such as Saphenous vein grafts (SVG) and thrombus containing lesions in acute MI angioplasty.
Objective: We sought to evaluate the long term outcomes of patients undergoing MGuard stenting at our center.
Methods & Results: The MGuard stent was utilized in 150 consecutive patients, 71% patients had SVG lesions and 29% were treated for native arteries during MI. The mean age was 69 years and 83% were males. The clinical presentation was STEMI in 30% and NSTEMI/UA in 60% of patients, 47% patients had DM and 29% sustained some degree of renal insufficiency. The mean stent length was 30±18 mm in vessels with a mean diameter of 3.4±0.5 mm. Clinical outcomes are shown in the Table:
Conclusions: In suitable patients within SVG and/or native coronary vessels during the course of MI, the MGuard stent seems to be a viable treatment strategy in PCI management of thrombus and\or friable atheromatous containing lesions
